Cancer Treatment Resistance: Why Cancer Comes Back and How to Fight It (2026)
What is cancer treatment resistance?
Cancer treatment resistance is the ability of cancer cells to survive and continue growing despite a therapy that should control them. It is a major reason a cancer can persist, progress or recur. Resistance can occur with chemotherapy, targeted therapy, endocrine therapy, immunotherapy and radiotherapy.
Some cancers are resistant from the outset. Others initially shrink or stabilize and later adapt. Tumours are not uniform masses: different cell populations can carry different genetic changes and respond differently to treatment. Therapy can select for cells that are less sensitive to the treatment.
| Type | What it means | Clinical implication |
|---|---|---|
| Intrinsic (primary) resistance | The cancer does not respond adequately from the start. | Clinicians re-check diagnosis, staging and predictive biomarkers; another treatment class or trial may be appropriate. |
| Acquired (secondary) resistance | The cancer initially benefits, then progresses because resistant clones or adaptive states emerge. | A repeat tissue biopsy and/or validated liquid biopsy may reveal a new actionable alteration or a change in tumour biology. |
| Mixed or oligoprogression | Only some sites progress while others remain controlled. | Selected patients may benefit from local treatment to progressing sites while systemic therapy continues; this is disease- and patient-specific. |
Why cancer becomes resistant: nine major mechanisms
1. Tumour heterogeneity and evolution
Cells within the same tumour or between primary and metastatic sites may differ genetically and biologically. A drug can eliminate sensitive cells while a pre-existing resistant clone survives and expands. New mutations, copy-number changes, epigenetic shifts and lineage changes can also arise under treatment pressure.
2. Cancer stem-cell-like states and cellular plasticity
Some cancer cells can enter a stem-like, slow-cycling or “persister” state. These states are associated with self-renewal, efficient damage responses, drug transport and the ability to repopulate a tumour after treatment.
3. Drug efflux and altered drug handling
Transport proteins, including ATP-binding cassette transporters, can pump some medicines out of cells. Cells may also alter drug uptake, activation, breakdown or sequestration, lowering the active drug concentration where it is needed.
4. Stronger DNA repair and damage tolerance
Chemotherapy and radiotherapy often work by causing DNA damage. Cancer cells can resist by restoring or increasing repair pathways, tolerating damage, or changing cell-cycle checkpoints.
5. Evasion of apoptosis
Many treatments rely on pushing damaged cancer cells into programmed cell death. Changes in TP53-related signaling, BCL-2 family proteins and survival pathways can raise that threshold.
6. Epithelial–mesenchymal transition and lineage transformation
EMT is a reversible cell-state programme linked with invasion, metastasis and treatment tolerance. In some cancers, resistance involves a more dramatic lineage transformation or change in histology, making a new biopsy important.
7. The tumour microenvironment
Fibroblasts, blood vessels, extracellular matrix, low oxygen, macrophages and other nearby cells can shield tumour cells, alter drug delivery and promote growth signals.
8. Immune escape
For immunotherapy, cancer may reduce antigen presentation, disrupt interferon signaling, exclude T cells, recruit suppressive immune cells or activate alternative inhibitory pathways.
9. Metabolic adaptation
Cancer cells can reroute use of glucose, glutamine, lipids and oxygen to maintain energy, redox balance and survival during stress. Most metabolism-directed combinations remain investigational rather than routine cancer care.
How resistance differs across cancer treatments
| Treatment type | Common resistance patterns | Examples of evidence-based responses |
|---|---|---|
| Chemotherapy | Drug efflux; altered drug metabolism; enhanced DNA repair; apoptosis evasion; slow-cycling cells; poor tumour penetration. | Change regimen or sequence; use a non-cross-resistant class when appropriate; incorporate surgery, radiation or targeted treatment when indicated by cancer-specific guidelines. |
| Targeted therapy | Mutation in the drug target; amplification or activation of a bypass pathway; downstream signaling changes; histologic transformation. | Re-profile tumour tissue or plasma when clinically appropriate; switch to a treatment targeting the newly actionable alteration or pathway. For example, resistance mutations have informed successive EGFR-directed strategies in some non-small-cell lung cancers.7 |
| Endocrine therapy | Alterations in hormone receptors or their signaling; activation of PI3K/AKT/mTOR or cell-cycle pathways; loss of hormone dependence. | Reassess receptor status and actionable mutations where guidelines support it; use cancer-specific endocrine sequencing and validated targeted combinations. ctDNA has defined uses in selected advanced breast-cancer settings, but a negative blood result may require tissue testing.8 |
| Immunotherapy | Low or altered antigen presentation; T-cell exclusion/exhaustion; suppressive microenvironment; alternative checkpoints; immune editing. | Confirm true progression and review for treatment-related patterns; use approved combinations or subsequent therapy only for the relevant cancer and setting; consider trials designed around immune resistance. |
| Radiotherapy | DNA-damage repair; hypoxia; cell-cycle effects; stem-like states; altered tumour vasculature and microenvironment. | Modern treatment planning, appropriately selected radiosensitizing systemic therapy, surgery or systemic therapy can be considered by a radiation oncologist and multidisciplinary team. Re-irradiation is highly site-, dose- and risk-dependent. |
What clinicians can do when resistance is suspected
1. Confirm what is changing
Progression should be interpreted in context: symptoms, physical examination, imaging trend, pathology, treatment timing and—in selected settings—tumour markers. Not every scan change is resistance; infection, inflammation, treatment effect or a second condition can sometimes mimic progression.
2. Revisit pathology and biomarker testing
Biomarker testing examines genes, proteins or other tumour features that may predict benefit from a treatment. Relevant tests may include validated DNA/RNA sequencing, immunohistochemistry, receptor status, MSI/dMMR, selected gene fusions or mutations, and tumour mutational burden where clinically indicated.
3. Consider repeat tissue biopsy and/or liquid biopsy
A new tissue biopsy can test a progressing lesion directly and may reveal a targetable mutation or histologic transformation. A liquid biopsy measures tumour-derived material in blood, commonly circulating tumour DNA (ctDNA), and can be useful when tissue is hard to obtain or for specific validated treatment decisions. A negative liquid biopsy should not be treated as proof that a relevant alteration is absent when tissue testing is feasible.
4. Change treatment based on the resistance biology
Options can include a new therapy against an acquired target, a switch to a different drug class, an approved combination, or a planned sequence of treatments. Evidence is specific to the cancer type, molecular finding, line of treatment and patient.
5. Use local therapy for selected limited progression
When only one or a few areas progress, a multidisciplinary team may consider surgery, ablation or radiation to those sites while controlling disease elsewhere with systemic therapy.
6. Discuss a clinical trial early
Clinical trials may test a resistance-matched treatment, a new combination, a sequencing strategy or improved monitoring. Ask the oncology team about trials when resistance is identified—not only after standard options are exhausted.
7. Bring the case to a multidisciplinary team
Complex resistance is best considered with medical, surgical and radiation oncology; pathology; radiology; molecular tumour board; genetics; and palliative/supportive care.
Questions to ask your oncology team
- Has progression been confirmed, and is it occurring everywhere or only at a few sites?
- Should the pathology, receptor status or stage be re-reviewed?
- Would a new tissue biopsy change management? Is a validated liquid biopsy appropriate?
- Which biomarkers are recommended for my cancer at this point?
- Is there an approved treatment that addresses the suspected resistance mechanism?
- Could local treatment control an isolated progressing lesion?
- Is there a suitable clinical trial or a value in referral to a specialist cancer centre?
Evidence hierarchy: what “promising” should mean
| Level of evidence | How to interpret it |
|---|---|
| Highest | Cancer-specific clinical guidelines, systematic reviews of well-conducted trials, and randomized phase III trials showing meaningful patient outcomes (survival, quality of life or validated clinical benefit). |
| Useful but narrower | Phase I/II trials, high-quality prospective cohort studies, and regulatory approvals for a defined biomarker and indication. Results may not apply outside that population. |
| Hypothesis-generating | Laboratory studies, animal models, case reports, retrospective associations and small uncontrolled series. These can guide research but do not establish a safe or effective treatment for an individual. |
| Not evidence of efficacy | Testimonials, social-media claims, mechanistic arguments alone, and products marketed without oncology-quality clinical data. |
Investigational and repurposed approaches: important boundaries
“Repurposed” medicines are drugs developed for another condition and evaluated for cancer. They should be used for cancer only when they are part of an approved, guideline-supported indication or a properly supervised clinical trial. Potential interactions with chemotherapy, targeted therapy, anticoagulants, seizure medicines and supportive drugs can be serious.
Related OneDayMD guides
- Cancer Biomarkers Explained: PD-L1, MSI-H/dMMR, TMB, ctDNA and more
- Liquid Biopsy and ctDNA: What Blood Tests Can—and Cannot—Tell Us
- Cancer Stem Cells: What They Are and Why They Matter
Frequently asked questions
Can cancer become resistant to treatment?
Yes. Some cancers are resistant from the beginning, while others develop resistance after an initial response. The next step is to confirm progression and determine whether a new biopsy, biomarker test or different treatment approach could change care.
Does treatment resistance mean cancer is terminal?
No. Resistance to one treatment is not necessarily resistance to all treatment. Depending on the cancer, clinicians may have other approved therapies, local treatment options, biomarker-matched treatments or clinical trials.
Can a liquid biopsy show why a cancer stopped responding?
Sometimes. ctDNA testing can detect certain actionable changes in blood and is useful in specific clinical settings. But it can miss alterations and cannot replace tissue in every situation.
Can diet, supplements or repurposed drugs reverse treatment resistance?
There is no general, proven diet, supplement or repurposed-drug regimen that reverses cancer treatment resistance. Discuss any product with the oncology team because interactions and delays in effective care can cause harm.
When should I ask about a clinical trial?
Ask when resistance is identified or when a treatment decision is being made. An early discussion can preserve options.
References and further reading
- Kozłowska K, et al. Multilevel Mechanisms of Cancer Drug Resistance. International Journal of Molecular Sciences. 2024;25(22):12402.
- Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer. PMID:39757310.
- Drug resistance mechanisms in cancers: Execution of pro-survival strategies. Journal of Biomedical Research. 2024;38(2):95-121.
- Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance. Annual Review of Immunology. 2024.
- National Cancer Institute. Biomarker Testing for Cancer Treatment.
- Pascual J, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer. Annals of Oncology. 2022;33:750-768.
- National Cancer Institute. Steps to Find a Clinical Trial.
Ask your oncology team for a clear explanation of the pattern of progression, pathology and biomarker results, and whether a second opinion or clinical-trial referral is appropriate.
.png)
.png)
Comments
Post a Comment